Table I.
In vitro activity of cabazitaxel and docetaxel against PPTP cell lines
| Cell Line | Histotype | rIC50 (nM) |
Panel rIC50/ Line rIC50 |
Ymin (Observed) |
Estimated Ymin* |
Relative In/Out (Observed Ymin) |
|---|---|---|---|---|---|---|
| Cabazitaxel | ||||||
| RD | Rhabdomyosarcoma | 0.51 | 0.92 | 9.9 | 8.6 | 5% |
| Rh41 | Rhabdomyosarcoma | 0.50 | 0.94 | 6.8 | 7.9 | −69% |
| Rh18 | Rhabdomyosarcoma | 0.17 | 2.82 | 51.4 | 50.5 | 12% |
| Rh30 | Rhabdomyosarcoma | 0.18 | 2.55 | 15.0 | 19.2 | −9% |
| BT-12 | Rhabdoid | 0.54 | 0.87 | 4.9 | 5.7 | −40% |
| CHLA-266 | Rhabdoid | 0.42 | 1.12 | 21.5 | 23.0 | −18% |
| TC-71 | Ewing sarcoma | 0.18 | 2.65 | 0.1 | 0.0 | −95% |
| CHLA-9 | Ewing sarcoma | 0.17 | 2.85 | 2.5 | 3.4 | −30% |
| CHLA-10 | Ewing sarcoma | 0.14 | 3.33 | 4.7 | 5.8 | −25% |
| CHLA-258 | Ewing sarcoma | 0.18 | 2.58 | 15.5 | 17.1 | −60% |
| SJ-GBM2 | Glioblastoma | 0.31 | 1.53 | 5.2 | 6.4 | −47% |
| NB-1643 | Neuroblastoma | 0.45 | 1.05 | 1.9 | 2.3 | −91% |
| NB-EBc1 | Neuroblastoma | 0.89 | 0.53 | 3.8 | 4.1 | −83% |
| CHLA-90 | Neuroblastoma | 0.84 | 0.56 | 12.2 | 13.2 | −56% |
| CHLA-136 | Neuroblastoma | 1.16 | 0.41 | 11.4 | 11.1 | −60% |
| NALM-6 | ALL | 0.57 | 0.82 | 0.0 | 0.0 | −99% |
| COG-LL-317 | ALL | 0.44 | 1.07 | 0.0 | 0.0 | −100% |
| RS4;11 | ALL | 0.57 | 0.82 | 1.3 | 0.0 | −91% |
| MOLT-4 | ALL | 0.29 | 1.61 | 0.2 | 0.0 | −98% |
| CCRF-CEM (1) | ALL | 0.57 | 0.83 | 0.2 | 0.0 | −96% |
| CCRF-CEM (2) | ALL | 0.49 | 0.95 | 0.1 | 0.0 | −98% |
| Kasumi-1 | AML | 0.86 | 0.54 | 8.1 | 9.9 | −72% |
| Karpas-299 | ALCL | 0.29 | 1.61 | 4.2 | 6.7 | −46% |
| Ramos-RA1 | NHL | 0.64 | 0.73 | 0.0 | 0.0 | −100% |
| Median | 0.47 | 1.00 | 4.5 | 5.8 | −65% | |
| Minimum | 0.14 | 0.41 | 0.0 | 0.0 | −100% | |
| Maximum | 1.16 | 3.33 | 51.4 | 50.5 | 12% | |
| Docetaxel | ||||||
| RD | Rhabdomyosarcoma | 0.77 | 1.14 | 8.08 | 12.5 | 3% |
| Rh41 | Rhabdomyosarcoma | 0.89 | 0.99 | 7.09 | 9.7 | −68% |
| Rh18 | Rhabdomyosarcoma | 0.30 | 2.93 | 50.00 | 51.5 | 10% |
| Rh30 | Rhabdomyosarcoma | 0.51 | 1.71 | 15.26 | 17.0 | −8% |
| BT-12 | Rhabdoid | 0.67 | 1.31 | 4.95 | 5.3 | −40% |
| CHLA-266 | Rhabdoid | 1.19 | 0.74 | 19.43 | 19.2 | −26% |
| TC-71 | Ewing sarcoma | 0.44 | 2.02 | 0.03 | 0.0 | −98% |
| CHLA-9 | Ewing sarcoma | 0.42 | 2.10 | 1.76 | 0.0 | −51% |
| CHLA-10 | Ewing sarcoma | 0.31 | 2.88 | 3.13 | 4.2 | −50% |
| CHLA-258 | Ewing sarcoma | 0.41 | 2.15 | 15.23 | 15.9 | −61% |
| SJ-GBM2 | Glioblastoma | 0.80 | 1.10 | 4.07 | 5.7 | −59% |
| NB-1643 | Neuroblastoma | 1.05 | 0.84 | 2.19 | 0.0 | −90% |
| NB-EBc1 | Neuroblastoma | 6.15 | 0.14 | 3.53 | 0.0 | −85% |
| CHLA-90 | Neuroblastoma | 2.23 | 0.39 | 11.48 | 14.2 | −59% |
| CHLA-136 | Neuroblastoma | 3.84 | 0.23 | 10.16 | 0.0 | −65% |
| NALM-6 | ALL | 1.57 | 0.56 | 0.06 | 0.0 | −98% |
| COG-LL-317 | ALL | 1.27 | 0.69 | 0.02 | 0.0 | −100% |
| RS4;11 | ALL | 1.38 | 0.64 | 1.40 | 0.0 | −91% |
| MOLT-4 | ALL | 0.87 | 1.01 | 0.06 | 0.0 | −99% |
| CCRF-CEM (1) | ALL | 2.04 | 0.43 | 0.22 | 0.0 | −96% |
| CCRF-CEM (2) | ALL | 1.66 | 0.53 | 0.12 | 0.0 | −98% |
| Kasumi-1 | AML | 3.08 | 0.29 | 7.76 | 8.4 | −73% |
| Karpas-299 | ALCL | 0.59 | 1.49 | 4.31 | 6.8 | −45% |
| Ramos-RA1 | NHL | 0.52 | 1.70 | 0.00 | 0.0 | −100% |
| Median | 0.88 | 1.00 | 3.80 | 2.1 | −66% | |
| Minimum | 0.30 | 0.14 | 0.00 | 0.0 | −100% | |
| Maximum | 6.15 | 2.93 | 50.00 | 51.5 | 10% | |